Kumanan Wilson

Kumanan Wilson

MD, MSc, FRCPC

Senior Scientist, Methodological and Implementation Research

Ottawa Hospital Research Institute

Professor, Faculty of Medicine

University of Ottawa

Contact

613-798-5555 x13056

Ottawa Hospital, Civic Campus 1053 Carling Avenue, Box 209 Ottawa, ON K1Y 4E9

Bio

Dr. Kumanan Wilson is a specialist in General Internal Medicine at The Ottawa Hospital,  Chief Executive Officer/Chief Scientific Officer, Bruyère Research Institute, Vice President Research & Academic, Bruyère Continuing Care and Chief Scientific Officer of CANImmunize Inc.

A Professor and Faculty of Medicine Clinical Research Chair in Digital Health Innovation at the University of Ottawa, he is also a member of the University of Ottawa’s Centre for Health Law, Policy and Ethics.

Dr. Wilson is the co-founder of CANImmunize, a science-based technology company specializing in immunization software that spun out from The Ottawa Hospital in 2019. To help Canadians keep track of their vaccinations, the team developed CANImmunize, a pan-Canadian digital immunization tracking system available as a mobile app and through a web portal. Dr. Wilson and his team are currently focused on digital immunization solutions to help vaccination programs.

Dr. Wilson’s research focuses on digital health, immunization, pandemic preparedness and public health policy and innovation. His research on immunization has explored social media’s impact on vaccine hesitancy, evaluation of vaccine safety using health services data and vaccine policy, including advocating for vaccine injury compensation. Other research interests include blood safety and newborn screening, health ethics, law and policy.

He has received support from multiple organizations including the Canadian Institutes of Health Research (CIHR), the World Health Organization (WHO), The Bill & Melinda Gates Foundation and Canada’s Immunity Task Force.

Research Goals and Interests

Maternal Child Metabolomics Research  
Preterm birth is a major worldwide public health concern, however identifying preterm infants in low- and middle-income settings poses a challenge where availability of prenatal ultrasounds is limited. Dr. Wilson has received 3 million dollars in funding from the Bill & Melinda Gates Foundation to develop alternative methods of estimating newborn gestational age and early child health outcomes through the analysis of newborn heel prick and cord blood samples. This work will aid in developing population level estimates of preterm birth and guide the care of newborns in low resource settings.   

PHASE I: Developing a Gestational Age Algorithm   
Using Ontario newborn screens data, Dr. Wilson and his research team determined that the newborns of different stages of prematurity are metabolically distinct. This discovery led to the development of an algorithm based on newborn screening data capable of estimating gestational age to within one week of ultrasound-validated GA. The model was further validated in an ethnic subpopulation in Ontario whose mothers were recent landed immigrants. The model was further refined to facilitate its implementation in low resource settings by incorporating non-mass spectrometry derived analytes including  fetal-to-adult Hb ratio, thyroid stimulating hormone and 17-hydroxypogesterone.

PHASE II: International Validation of a Gestational Age Algorithm
We have tested the effectiveness of our algorithm in low resource settings in a prospective cohort study. Algorithms correctly estimated gestational age to within 1 week in heel and cord blood, with cord blood being a more feasible option in low-resource settings.

PHASE III: Implementation of a Gestational Age Algorithm
Dr Wilson his team in collaboration with researchers at Stanford University are currently conducting a pilot study at four international sites to implement the process of gestational age estimation. All sites are low resource settings with high rates of preterm birth and low access to ultrasound. Into the data screening process we have incorporated a protocol to identify select screen positive results and notify collection sites in real time in order to initiate treatment.

Research Collaborators

Steven Hawken, PhD

Pranesh Chakroborty, MD

Deschayne Fell, PhD

Mark Walker, MD


Publications
Wilson, Lindsay A, Fell, D. B., et al. (2019) ‘Association between newborn screening analytes and hypoxic ischemic encephalopathy.’, Scientific reports, 9(1), p. 15704. doi: 10.1038/s41598-019-51919-x.   

Wilson, LA, Murphy, M.SQ, Ducharme, R, Denize, K, Jadavji NM, Potter, B, Little J, Chakraborty P, Hawken S, Wilson K. (2019) ‘Postnatal gestational age estimation via newborn screening analysis: application and potential.’, Expert review of proteomics, 16(9), pp. 727–731. doi: 10.1080/14789450.2019.1654863. 

Murphy, MSQ, Hawken, S, Cheng, W, WIlson, LA, Lamoureux, M, Henderson M, Pervin, J, Chowdhury A, Gravett, C, Lackritz, E, Potter, BK, Walker M, Little J, Rahman A, Chakraborty P, Wilson, K. (2019) ‘External validation of postnatal gestational age estimation using newborn metabolic profiles in matlab, Bangladesh’, eLife. eLife Sciences Publications Ltd, 8. doi: 10.7554/eLife.42627. 

Fell DB, Wilson LA, Hawken S, Spruin S, Murphy MSQ, Potter BK, Little J, Chakraborty P, Lacaze-Masmonteil T, Wilson K.  Association between newborn screening analyte profiles and infant mortality.  Journal of Maternal-Fetal and Neonatal Medicine. 2019 May 21:1-4. doi: 10.1080/14767058.2019.1615048. 

 Murphy M, Chakraborty P, Pervin J, Rahman A, Wilson L, Lamoureux M, Denize K, Henderson M, Hawken S, Potter B, Little J, Wilson K.  Incidental screen positive findings in a prospective cohort study in Matlab, Bangladesh: insights into expanded newborn screening for low-resource settings.   Orphanet Journal of Rare Diseases. 2019 Jan 30;14(1):25. doi: 10.1186/s13023-018-0993-1 

Murphy, Malia S.Q. et al. (2018) ‘Metabolic profiles derived from residual blood spot samples: A longitudinal analysis’, Gates Open Research. F1000 Research, Ltd., 2, p. 28. doi: 10.12688/gatesopenres.12822.1. 

Sood MM, Murphy MSQ, Hawken S, Wong CA, Potter BK, Burns KD, TSampalieros A, Atkinson KM, Chakraborty P, Wilson K.  Association between newborn metabolic profiles and pediatric kidney disease.  Kidney International Reports.  May 2018;3(3):691-700.  doi: 10.1016/j.ekir.2018.02.001 

Wilson K, Duque DR, Murphy MS, Hawken S, Pham-Huy A, Kwong J, Deeks SL, Potter BK, Crowcroft NS, Bulman DE, Chakraborty P, Little J. T-cell receptor excision circle levels and safety of paediatric immunization: A population-based self-controlled case series analysis. Hum Vaccin Immunother.  2018 Jun 3;14(6):1378-1391. doi: 10.1080/21645515.2018.1433971. 

Fell DB, Hawken S, Wong CA, Wilson LA, Murphy MSQ, Chakraborty P, Lacaze-Masmonteil T, Potter BK, Wilson K. Using newborn screening analytes to identify cases of neonatal sepsis. Nature Scientific Reports. 2017; 7. doi:10.1038/s41598-017-18371-1

Hawken S, Ducharme R, Murphy MSQ, Atkinson KM, Potter BK, Chakraborty P, Wilson K. Validation of a gestational age prediction algorithm in ethnic subgroups using routinely collected newborn screening metabolic profiles. BMJ Open. 2017; 7:e015615. doi: 10.1136/bmjopen-2016-015615 

 Wilson K, Hawken S, Murphy M, Atkinson KM, Potter B, Sprague A, Walker M, Chakraborty P, Little J. Postnatal prediction of gestational age using newborn fetal hemoglobin levels. EBioMedicine. 2017; 15:203–209. doi: 10.1016/j.ebiom.2016.11.032

Wilson K, Hawken S, Potter B, Chakraborty P, Walker M, Ducharme R, Little J. Accurate prediction of gestational age using newborn screening analyte data. American Journal of Obstetrics and Gynecology.  2016 Apr; 214(4):513.e1-9 

Wilson K, Hawken S, Ducharme R, Potter BK, Little J, Thebaud B, Chakroborty P. (2014) ‘Metabolomics of prematurity: Analysis of patterns of amino acids, enzymes, and endocrine markers by categories of gestational age’, Pediatric Research, 75(2), pp. 367–373. doi: 10.1038/pr.2013.212. 



 


News


Publications

Coverage disparities and delayed immunization: Assessing 12-month vaccination completion in Canadian children using data from a digital immunization platform

2025-12-31 Go to publication

Necessary conditions for the future consideration of vaccine certificates

2025-12-31 Go to publication

Acceptability of patient-centered digital vaccine safety monitoring: A Canadian Immunization Research Network study

2025-12-31 Go to publication

Maternal Lipidomic Signatures of Preterm and Small-for-Gestational Age Infants in Low- and Middle-Income Countries

2025-12-03 Go to publication

Effect of Nonmedical Cannabis Legalization and Exposure to Retail Stores on Cannabis Harms

2025-11-25 Go to publication

Peer Reviewed

Bringing CT Head Rules, IA Risk Score and SAH Rule to the point of care using digital technologies: Development and evaluation of impact. The Ottawa Hospital Academic Medical Organization (TOHAMO) Innovation Fund Grant. Co-Principal Investigator. (Co-PI – Ian Stiell) – $99, 672

iOS APP to Assist End Stage Kidney Disease Patients with Phosphate Self-Management. The Ottawa Hospital Academic Medical Organization (TOHAMO) Innovation Fund Grant. Co-Principal Investigator. (Co-PI – Deborah Zimmerman) – $93 330

Reducing sudden cardiac death via ICT: coordinated use of information and communication technologies (ICT) to empower patients and their families to reduce sudden cardiac death post myocardial infarction - Development of “know your SCD risk and Ejection Fraction” Patient Empowerment ICT platform. Cardiac Arrhythmia Network of Canada (CANet). Co –Investigator. (PI- Calum Redpath) – $210,000

Development and validation of a prediction model for severe (hospitalized) RSV through the development of an ICES based RSV research platform. CHAMO Innovation Fund. Co –Investigator. (PI - Charles Hui) – $90,000

Development of a global algorithm for metabolic gestational age dating. The Bill & Melinda Gates Foundation. Principal Applicant –  $1,183,353 USD

Improving care for emergency department and Pre-hospital patients with acute and life-threatening conditions. Canadian Institutes of Health Research (CIHR) Foundation Scheme - FDN 143271. Co –Investigator. (PI - Ian Stiell) – $2,093,539

Ottawa Hospital Research Institute – Evidence Review Synthesis Centre. PHAC-NSHRF - Evidence Review Synthesis Centres. Co –Investigator. (PI - David Moher) – $200,000

Examining the relationship between repeated blood donations in female donors on maternal/neonatal outcomes: a cohort study. Canadian Institutes of Health Research/CBS Priority Announcement - Transfusion Science 201503-PH1. Co –Investigator (PI- Alan Tinmouth) – $135,657

Development and evaluation of a mobile App to promote the use of the Ottawa ankle rules and the Canadian C-spine rule. The Ottawa Hospital Academic Medical Organization (TOHAMO) Innovation Fund Grant. Principal Investigator – $99,900

Canadian Immunization Research Network. Canadian Institutes of Health Research. Co-Principal Investigator. (PI. Scott Halpern) – $6,583,497

Program Support Award for Canadian Transfusion Medicine and Science Research: University of Ottawa Centre for Transfusion Research. Canadian Blood Services. Co –Investigator (PI. Alan Tinmouth) – $718,286.81.

Emerging team grant in rare diseases: achieving the “triple aim” for inborn errors of metabolism. Canadian Institutes of Health Research. Co-Principal Investigator (PI: B. Potter) – $1,490,486

Non-Peer Reviewed

Microsoft Azure Research Award CRM:0518794. Principal Investigator – $20,000 USD

Development of a global algorithm for metabolic gestational age dating – Supplemental Funds. The Bill & Melinda Gates Foundation. Principal Applicant. $234,260 USD

Introducing Trade Names into ImmunizeCA. Sanofi-Pasteur Ltd. Principal Investigator – $88,050

Development of a mobile enhanced immunization information system. PHAC - Innovation Strategy Program. Principal Investigator – $3,489,139

Related Research at The Ottawa Hospital